Logo-ipp
Submitted: 30 Jan 2023
Accepted: 11 May 2023
ePublished: 22 Aug 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2024;10(2): e39489.
doi: 10.34172/ipp.2023.39489

Scopus ID: 85197754804
  Abstract View: 694
  PDF Download: 225

Original

Impact of COVID-19 on renal transplant recipients

Ganesan Geethanjali ORCID logo, Elumalai Ramprasad* ORCID logo, Sekar Manikantan ORCID logo, Matcha Jayakumar ORCID logo

1 Department of Nephrology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India
*Corresponding Author: Elumalai Ramprasad, Email: ramprasadnephro@gmail.com

Abstract

Introduction: It was essential to explore immunosuppressant management strategies and potential clinical variables associated with COVID-19 related mortality in order to provide insight for clinicians attempting to manage kidney transplant recipients during the ongoing severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic.

Objectives: The aim of the study was to assess the impact of COVID-19 on post-transplant renal function and outcome of immunosuppressant management on COVID-19.

Patients and Methods: This is a cross sectional observational study conducted from March 2020 to January 2022 in a tertiary care hospital in South India. Baseline characteristics, comorbidities, history of graft dysfunction, symptoms and immunosuppressant modification was noted. Outcomes of COVID-19 such as acute kidney injury (AKI), need for dialysis and post COVID-19 complications were noted. The statistics were expressed as percentage for categorical variables and mean ± SD for continuous variables.

Results: Out of 400 renal transplant patients on regular follow up, 28 patients developed COVID-19. The incidence of AKI was 64.2%. Immunosuppressant dose modification was done in majority of patients [mycophenolate mofetil (28.5%), steroids (53.5%) and tacrolimus (39.2%)]. Outcomes included recovery from AKI in 61.1%, recovery from oxygen dependence in 100% patients with an overall mortality rate of 7.1% patients. About 17.8% patients developed post-COVID-19 complications.

Conclusion: Immunosuppressant dose modification during COVID-19 could play a role in development of AKI; infection being an independent risk factor. Patients should be monitored for development of post-COVID-19 complications.


Citation: Geethanjali G, Ramprasad E, Manikantan S, Jayakumar M. Impact of COVID-19 on renal transplant recipients. Immunopathol Persa. 2024;10(2):e39489. DOI:10.34172/ ipp.2023.39489.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 695

Your browser does not support the canvas element.


PDF Download: 225

Your browser does not support the canvas element.